CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific...

Full description

Saved in:
Bibliographic Details
Main Authors DING, Yi, QIN, Beibei, WANG, Yongqiang, JHENG, Ming-Jin, ZHANG, Yun, YANG, Yunxing, WU, Yuetao, CHEN, Fei, ZHAO, Chuchu
Format Patent
LanguageEnglish
French
German
Published 19.06.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.
Bibliography:Application Number: EP20220757202